DotLab research highlights need for endometriosis test

Market research from the biotech company DotLab has highlighted the need for an endometriosis test.

The New-York-based company has shared primary, qualitative market research findings regarding receptivity to and interest in its novel endometriosis diagnostics.

The report has shown that 86 per cent of the patients surveyed found the DotEndo endometriosis test relevant to their situation, 96 per cent showed interest in learning more and 84 per cent said they would ask their OB/GYN about it.

DotEndo, a non-invasive blood test for endometriosis, works by measuring biomarkers in the blood and applying biostatistics to identify endometriosis.

The company says its recent findings suggest the unmet need for a test for endometriosis to triage patients toward the appropriate treatment or specialists early.

Endometriosis symptoms clinically overlap with other conditions, often making it difficult to identify the disease.

“It would be great to have a [diagnosis] before proceeding with a treatment, especially one that has side effects or potential morbidities,” said an OB/GYN who participated in the study.

The research, performed by a third party, has suggested that if the DotEndo test carries a low out-of-pocket patient cost or is covered by insurance, MDs would use the test broadly.

Similarly, patients said they would be interested in the test if it was within their desired price range, with 89 per cent saying they would pursue the test if it was covered by their insurance.

Patient Caitlin Hale, who did not participate in the research, said, “Looking back, an earlier endometriosis diagnosis would have saved my family and me years of pain, confusion, and financial stress.

“A non-invasive test could transform the lives of endometriosis patients by eliminating diagnostic delays and eradicating the normalisation and stigmatisation of menstrual pain.”

One in ten women suffer from endometriosis, but a diagnosis can take up to eleven years.

DotLab is hoping that its test will narrow the disparity of care for endometriosis patients and will provide answers to help speed up the diagnostic journey and prevent disease progression.